Generic Medicine Info
Indications and Dosage
Facilitate endotracheal intubation, Muscle relaxant in general anaesthesia
Adult: Initial dose: 80-100 mcg/kg. Subsequent doses: 10-20 mcg/kg. Initial dose following suxamethonium admin or in patients at high risk: 50-60 mcg/kg. Initial dose for caesarean section: 35 mcg/kg.
Special Precautions
Pulmonary disease, respiratory insufficiency, asthma, neuromuscular disease, dehydration, severely ill patients, hepatic or renal impairment. Doses in obese patients should be based on patient's ideal body weight. Pregnancy, lactation.
Adverse Reactions
Transient hypotension, bradycardia, reduced cardiac output.
Potentially Fatal: Anaphylactic reactions and malignant hyperthermia.
IV/Parenteral: C
Prolonged apnoea due to paralysis of the intercostal muscles and diaphragm, with CV collapse and effects of histamine release.
Drug Interactions
Actions antagonised by cholinesterases and long term carbamazepine, phenytoin or corticosteroids usage. Enhanced block when used with drugs that have neuromuscular blocking activity such as lidocaine, quinidine, verapamil and aminoglycosides.
Potentially Fatal: Effects enhanced by volatile inhalational anaesthetics, ketamine (IV), antiarrhythmics, antibacterials, K depleting diuretics, parenteral Mg salts.
Mechanism of Action: Pipecuronium bromide is an aminosteroidal competitive neuromuscular blocker. It does not have significant CV adverse effects or histamine-related effects.
Onset: Dose-dependent: 2.5-3 min.
Duration: Dose-dependent: 30 min-2 hr.
Distribution: Vd: 0.25 L/kg.
Metabolism: Converted to 3-desacetyl (less active).
Excretion: Via urine (as unchanged); 1.7-2.3 hr (elimination half-life).
MIMS Class
Neuromuscular Blocking Agents
Disclaimer: This information is independently developed by MIMS based on Pipecuronium from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in